Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Continuous ICM monitoring in heart failure uncovered a high arrhythmia burden, including atrial fibrillation, bradyarrhythmia, and VT/VF, which was linked to more interventions, hospitalizations, and heart failure events.
Continuous implantable monitoring in heart failure revealed a high burden of arrhythmias, strongly linked to hospitalizations and treatment changes, but not reduced by protocol-directed congestion management.
Smartphone photoplethysmography before planned cardioversion reduced same-day cancellations in patients with atrial fibrillation or flutter by detecting spontaneous return to sinus rhythm early.
Thyroid dysfunction reshapes lipid metabolism, vascular tone, cardiac performance, and rhythm. Cardiovascular risk is clearest at the extremes of thyroid status, while treatment decisions in subclinical disease should remain individualized.
Continuous ICM monitoring in heart failure found a high burden of atrial fibrillation, bradyarrhythmia, and VT/VF. Arrhythmias were linked to more interventions and higher hospitalization risk, but the congestion-management strategy did not
In OPINION, prophylactic left atrial appendage occlusion during valve surgery did not significantly lower stroke, TIA, or cardiovascular death at 1 year in patients without pre-operative atrial fibrillation.
This review analyzes the landmark SWISS-AF study, demonstrating that serum neurofilament light chain (sNfL), traditionally a marker of neuronal damage, is a potent independent predictor of major vascular events, heart failure, and mortality
A large Dutch primary care cohort links subclinical hyperthyroidism to higher risks of atrial fibrillation, heart failure, and all-cause mortality, with particularly notable relative risks in younger adults and in patients with more strongl
In ARIC, ischemic stroke at age 80 years or older was more often embolic than thrombotic. Atrial fibrillation and left atrial disease explained much of the age effect, and adding embolic factors improved prediction.
In a patient-level meta-analysis of 10,212 Asian and 61,471 non-Asian AF patients, standard-dose DOACs outperformed warfarin more strongly in Asians, with less stroke, major bleeding, and net clinical harm. Standard-dose therapy was favored
Shorter pre-treatment fibrin clot lysis time independently predicts higher bleeding risk in AF patients on oral anticoagulation, as evidenced by the ARISTOTLE trial.
Researchers identify JNK2 as a key mediator in gut-heart crosstalk, linking intestinal permeability to atrial fibrillation pathogenesis through inflammatory stress signals, offering new therapeutic targets.
A VITAL-AF trial analysis reveals that combining ECG-based artificial intelligence with clinical risk scores significantly improves atrial fibrillation screening efficiency. The study demonstrates that high-risk individuals benefit most fro
Subgroup analysis of the OPTIMAS trial reveals that neither the timing of atrial fibrillation diagnosis nor AF subtype modifies the treatment effect of early versus delayed direct oral anticoagulant initiation in acute ischemic stroke. Pers
This phase 2 trial demonstrates that memantine, an NMDA receptor antagonist, significantly reduces premature atrial contractions (PACs) and nonsustained atrial tachycardia burden, suggesting the cardiac glutamatergic system as a novel thera
A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populat
Recent data from the ARIC study and emerging expert consensus are redefining primary aldosteronism. Rather than a rare, all-or-nothing condition, it is now viewed as a broad spectrum where even subclinical elevations significantly increase
This review analyzes the STABLED trial findings alongside major AFib rhythm control studies, evaluating the efficacy and safety of catheter ablation added to DOAC therapy for secondary stroke prevention.
The SCENA-AF trial highlights the efficacy of nanosecond pulsed field ablation (nsPFA) for treating paroxysmal atrial fibrillation, achieving an 88.49% success rate at 12 months with minimal complications and a significant shift toward loca
The DARE-AF trial demonstrates that 10 mg of dapagliflozin for three months does not significantly reduce early arrhythmia recurrence or AF burden following catheter ablation in patients without existing indications for SGLT2 inhibitors.